Cilostazol in a Child With Moyamoya Disease.

J Child NeurolJan 8, 2026 (epub)

Alizah A Patterson, Sarah K D Vogel, April Sharp et al.

✦ AI-curated · Sources linked

Case in brief

A 9-year-old girl with moyamoya disease was diagnosed after a large right middle cerebral artery stroke. Following pial synangiosis, she developed frequent transient episodes of dysarthria and left-sided drooling. The episodes persisted despite trials of antiseizure medications and blood pressure augmentation, then abated after cilostazol was added. When episodes recurred, they again subsided after the cilostazol dose was adjusted.

What made this case unusual

The report describes cilostazol use for recurrent transient neurologic events in a child with moyamoya after pial synangiosis, an area where pediatric safety and efficacy were stated to be unknown.

Diagnostic / clinical pearl

In this case, recurrent transient neurologic events after pial synangiosis abated with cilostazol and again subsided after dose adjustment; the report does not establish efficacy or safety in other children.

Why it matters

The case highlights the limited evidence for nonsurgical interventions in pediatric moyamoya and the need for further investigation of cilostazol.

Source

Published in J Child Neurol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.